Thanks Orb.
I found something very interesting on the updated website when I clicked
Company/Strategy
read what I found below:
Partnerships are structured such that the partner company is responsible for the complex later stages of drug development and therefore the financial burden and the risks associated with drug failure. With a few partnerships in place, Phylogica is cash flow positive. Furthermore as ongoing milestone payments can begin a few months after commencing the collaboration, thus a strong asset base can be quickly established.
Interesting we are now cash flow positive.
Bring on the AGM.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.045(3.13%) |
Mkt cap ! $813.6M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.46 | $1.36 | $314.1K | 222.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 330 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 12708 | 2 |
View Market Depth
| Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |